Merck & Co.
AWARDS
NEWS
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
PCSK9 inhibitors have had trouble gaining tracking in the marketplace. Since about 2015, a number of companies have received approval for these drugs but struggled with sales.
It was another busy week for clinical trial news. Here’s a look.
Organon is paying $75 million upfront, taking on about $9 million of Forendo debt, and up to $270 million in various development and regulatory milestones.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Merck and Ridgeback Biotherapeutics’ antiviral drug molnupiravir, which showed great promise against COVID-19 in clinical trials, received its first authorization.
JOBS
IN THE PRESS